Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A comparison of antithrombin III procedures.

M Rose, C S Wideman, B L Evatt

    Clinical and Laboratory Haematology
    |January 1, 1983
    PubMed
    Summary

    Antithrombin III (AT III) deficiency can cause severe blood clots. Standardized assays are needed to accurately measure AT III levels in patients with congenital or acquired deficiencies to improve diagnosis and treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016
    Same author

    The AIDS epidemic in haemophilia patients II: pursuing absolute viral safety of clotting factor concentrates 1985-1988.

    Haemophilia : the official journal of the World Federation of Hemophilia·2012
    Same author

    4-Nonylphenol (NP) in food-contact materials: analytical methodology and occurrence.

    Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment·2008
    Same author

    The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology.

    Arthritis and rheumatism·2008
    Same author

    Is there any role for computed tomography measurements of medial temporal lobe atrophy in dementia? A review of the literature and case series from a memory clinic.

    Internal medicine journal·2008
    Same author

    Oculopharyngeal myopathy with inflammation and calcinosis: an unusual phenotype.

    Journal of neurology, neurosurgery, and psychiatry·2008

    Area of Science:

    • Biochemistry
    • Hematology
    • Clinical Chemistry

    Background:

    • Antithrombin III (AT III) is a key inhibitor of blood clotting factors.
    • Hereditary AT III deficiency is linked to recurrent deep-vein thrombosis and pulmonary emboli.
    • Diagnosing acquired AT III deficiency is challenging due to non-standardized and incomparable assay methods.

    Purpose of the Study:

    • To compare the performance of different assays in measuring Antithrombin III levels.
    • To evaluate the ability of current AT III measurement procedures in various disease states.
    • To address the lack of standardization in AT III assays for acquired deficiency detection.

    Main Methods:

    • Utilized immunoelectrophoretic, chromogenic, and clottable assays.
    • Measured Antithrombin III levels in patients with congenital AT III deficiency.
    Keywords:
    BiologyBlood Coagulation Effects--analysisClinical ResearchDiseasesEmbolismEvaluationExaminations And DiagnosesGeneticsHematological EffectsHemic SystemHereditary DiseasesLaboratory Examinations And DiagnosesLaboratory ProceduresLiver DysfunctionOral ContraceptivesPhysiologyResearch MethodologyThromboembolismThrombosisVascular Diseases

    Related Experiment Videos

  • Assessed Antithrombin III levels in patients with suspected acquired AT III deficiency.

    • Main Results:

    • Different AT III assays measure distinct components, leading to incomparable results.
    • Immunoelectrophoretic, chromogenic, and clottable assays showed variability in measuring AT III.
    • The study highlighted discrepancies in AT III quantification across various methodologies.

    Conclusions:

    • Standardization of Antithrombin III assays is crucial for accurate diagnosis of both congenital and acquired deficiencies.
    • Inconsistent assay results hinder the identification of patients at risk for thromboembolic disease.
    • Further research is needed to establish reliable and comparable methods for AT III level determination.